IFNG and neoplasm: (104) showed that neoadjuvant pembrolizumab-mediated PD-1 blockade led to an increase of intratumoral T cells, upregulated expression of IFN-γ–related genes, and downregulated expression of cell cycle-related genes, effectively enhancing the local and systemic anti-tumor effect in patients.